2031年病毒性呼吸道感染治疗市场规模分析

Global Viral Respiratory Infections Treatment Market

市场规模（十亿美元）

CAGR : 8.50 %

Forecast Period	2024 –2031
Market Size (Base Year)	USD 57,365.34 Million
Market Size (Forecast Year)	USD 108,207.05 Million
CAGR	8.50 %
Major Markets Players	Pfizer GSK Gilead Sciences F. Hoffmann La Roche Johnson & Johnson

>全球病毒性呼吸道感染治疗市场，按治疗类型（抗病毒药物、疫苗、单克隆抗体、非甾体抗炎药 (NSAID) 等）、类型（非处方药和处方药）、给药途径（口服、鼻腔和注射）、疾病类型（新冠病毒、流感 (FLU)、呼吸道合胞病毒 (RSV)、副流感病毒、腺病毒、鼻病毒（普通感冒）、肠道病毒、抗炎等）、感染类型（上呼吸道感染和下呼吸道感染）、人群（儿童、成人和老年人）、性别（男性和女性）、最终用户（医院、家庭护理机构、诊所、研究机构和学术中心以及门诊手术中心）、分销渠道（直接招标、零售销售等）划分 - 行业趋势与预测2031年。

病毒性呼吸道感染治疗市场分析及规模

病毒性呼吸道感染的日益流行推动了市场的增长。然而，严格的监管审批流程限制了市场的增长。另一方面，日益增多的合作研究活动和伙伴关系预计将为市场增长创造机会。

Data Bridge Market Research 分析，全球病毒性呼吸道感染治疗市场预计将从 2023 年的 573.6534 亿美元增至 2031 年的 1082.0705 亿美元，在 2024 年至 2031 年的预测期内以 8.5% 的复合年增长率增长。

报告指标	细节
预测期	2024 至 2031 年
基准年	2023
历史性的一年	2022（可定制 2016-2021）
定量单位	收入（百万美元）
涵盖的领域	治疗类型（抗病毒药物、疫苗、单克隆抗体、非甾体抗炎药 (NSAID) 等）、类型（非处方药和处方药）、给药途径（口服、鼻腔和注射）、疾病类型（新冠病毒、流感 (FLU)、呼吸道合胞病毒 (RSV)、副流感病毒、腺病毒、鼻病毒（普通感冒）、肠道病毒、抗炎药等）、感染类型（上呼吸道感染和下呼吸道感染）、人群（儿童、成人和老年人）、性别（男性和女性）、最终用户（医院、家庭护理机构、诊所、研究机构和学术中心以及门诊手术中心）、分销渠道（直接招标、零售销售等）
覆盖国家	美国、加拿大、墨西哥、德国、意大利、英国、法国、瑞士、西班牙、俄罗斯、土耳其、比利时、荷兰、欧洲其他地区、中国、印度、韩国、日本、泰国、澳大利亚、新加坡、印度尼西亚、马来西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列以及中东和非洲其他地区
涵盖的市场参与者	辉瑞公司、葛兰素史克公司、吉利德科学公司、罗氏公司、强生公司、科兴家族、礼来公司、阿斯利康公司、再生元制药公司、Bharat Biotech、Swedish Orphan Biovitrum AB (publ)、印度血清研究所私人有限公司、Biological E Limited、Celltrion Healthcare Co.,Ltd.、InflaRx NV 等

市场定义

病毒性呼吸道感染的治疗包括多种医疗程序，旨在对抗影响呼吸系统的病毒引起的疾病。许多疾病，包括普通感冒、流感、呼吸道合胞病毒 (RSV)、腺病毒，以及最近的新病毒，如导致 COVID-19 的 SARS-CoV-2，都是由这些疾病引起的，这些疾病主要影响鼻子、喉咙、鼻窦和肺部。通常使用各种策略来治疗这些疾病，例如抗病毒药物、减轻症状的支持性护理、预防特定疾病的免疫接种，以及在更严重的情况下，使用氧气治疗或机械通气等尖端技术住院治疗。医学科学的进步不断推动着新型抗病毒药物、疫苗接种和治疗方法的开发，以提高治疗效果、减轻症状强度并阻止这些极具传染性的呼吸道感染的传播。

全球病毒性呼吸道感染治疗市场动态

本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：

驱动程序

病毒性呼吸道感染患病率不断上升

流感、呼吸道合胞病毒 (RSV) 等呼吸道感染的发病率不断上升，以及 COVID-19 疫情在全球的影响，推动了对有效治疗方案的需求。全球人口不断增长，再加上城市化和国际旅行等因素，导致呼吸道病毒迅速传播，从而形成了大量需要治疗干预的患者群体。

政府举措和疫苗接种计划

世界各国政府认识到病毒性呼吸道感染对公众健康的重大影响，正在实施战略举措，遏制病毒性呼吸道感染的传播。最有效的措施之一是推广和广泛实施旨在预防流感、肺炎和 COVID-19 等主要病毒性呼吸道感染的疫苗接种计划。各国政府正在投入大量资源，确保疫苗的广泛可及性和可负担性，从而促进全球疫苗接种覆盖率的提高。

机会

不断增多的合作研究活动和伙伴关系

由于病毒性呼吸道疾病的复杂性，有必要采取一种结合制药公司、学术机构、政府和医疗保健组织之间伙伴关系的多学科战略。结合资源、信息和技能的合作研究计划加快了病毒性呼吸道感染治疗的创新速度。合作促进了信息、科学发现和技术创新的交流，从而更深入地了解病毒、病毒的运作方式和可能的治疗方法。这些伙伴关系为更有效的药物开发和发现程序提供了途径。与单独工作相比，当研究人员汇集各种观点和专业知识时，他们可以更快、更有效地找到新的治疗目标、创造创新的抗病毒药物并开发疫苗接种技术。

克制/挑战

对熟练医务人员的依赖

病毒性呼吸道感染的有效诊断和治疗通常需要医护人员具备丰富的专业知识和经验。技术人员的短缺（尤其是在某些地区）阻碍了医疗服务的无缝交付，并限制了市场的增长潜力。

病毒性呼吸道感染的管理十分复杂，包括准确诊断、选择适当的治疗方法和患者护理，因此需要具备专业技能的劳动力。传染病专家、肺病专家和呼吸治疗师等合格医疗专业人员的短缺，阻碍了及时有效地提供医疗服务。对熟练劳动力的这种依赖，在缺乏专业医疗人员的地区造成了瓶颈。

最新动态

2023 年 8 月，再生元制药公司与美国生物医学高级研究与发展局 (BARDA) 达成协议，为预防 SARS-CoV-2 感染的新型 COVID-19 单克隆抗体疗法的临床开发、临床制造和监管许可流程提供支持
2023年7月，科兴生物与PT Biofarma宣布两家企业在服务印尼家庭疫苗接种市场及全球市场的合作上迈出了重要一步

全球病毒性呼吸道感染治疗市场范围

全球病毒性呼吸道感染治疗市场根据治疗类型、类型、给药途径、疾病类型、感染类型、人口、性别、最终用户和分销渠道分为九个显著部分。

治疗类型

抗病毒药物
疫苗
单克隆抗体
非甾体抗炎药 (NSAID)
其他的

根据治疗类型，市场分为抗病毒药物、疫苗、单克隆抗体、非甾体抗炎药 (NSAID) 等。

类型

场外交易
处方药

根据类型，市场分为非处方药和处方药。

给药途径

口服
鼻腔
注射剂

根据给药途径，市场分为口服、鼻腔和注射。

疾病类型

冠状病毒
流感（FLU）
呼吸道合胞病毒 (RSV)
副流感病毒
腺病毒
鼻病毒（普通感冒）
肠道病毒
其他的

根据疾病类型，市场细分为 covid、流感 (flu)、呼吸道合胞病毒 (RSV)、副流感病毒、腺病毒、鼻病毒 (普通感冒)、肠道病毒等。

感染类型

上呼吸道感染
下呼吸道感染

根据感染类型，市场分为上呼吸道感染和下呼吸道感染。

人口

儿科
成年人
老年

根据人口，市场分为儿科、成人和老年人。

性别

男性
女性

根据性别，市场分为男性和女性。

最终用户

医院
家庭护理设置
诊所
研究机构和学术中心
门诊手术中心

根据最终用户，市场分为医院、家庭护理机构、诊所、研究机构和学术中心以及门诊手术中心。

分销渠道

直接招标
零售销售
其他的

根据分销渠道，市场分为直接招标、零售销售和其他。

全球病毒性呼吸道感染治疗市场区域分析/见解

全球病毒性呼吸道感染治疗市场根据治疗类型、类型、给药途径、疾病类型、感染类型、人口、性别、最终用户和分销渠道分为九个显著部分。

本市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、意大利、英国、法国、瑞士、西班牙、俄罗斯、土耳其、比利时、荷兰、欧洲其他地区、中国、印度、韩国、日本、泰国、澳大利亚、新加坡、印度尼西亚、马来西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列以及中东和非洲其他地区。

由于投资巨大且技术进步不断进步，北美有望在市场中占据主导地位。美国有望在北美地区占据主导地位，因为美国拥有完善的医疗保健体系，其特点是先进的医疗设施、尖端的研究机构和完善的监管框架。德国有望在欧洲地区占据主导地位，因为它拥有卓越的医疗保健基础设施、领先的制药公司集中、严格的监管标准、战略地理位置以及对公共卫生的积极态度。中国有望在亚太地区占据主导地位，因为中国的制药行业发展迅速，注重创新。国内外制药公司的存在促进了一个充满活力的生态系统，鼓励开发新型抗病毒药物和疗法。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响以及贸易路线。

竞争格局和全球病毒性呼吸道感染治疗市场份额分析

全球病毒性呼吸道感染治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

全球病毒性呼吸道感染治疗市场的一些主要市场参与者包括辉瑞公司、葛兰素史克公司、吉利德科学公司、罗氏有限公司、强生公司、科兴生物、礼来公司、阿斯利康、再生元制药公司、巴拉特生物技术公司、瑞典孤儿生物维特鲁姆公司 (publ)、印度血清研究所私人有限公司、Biological E 有限公司、Celltrion Healthcare 有限公司、InflaRx NV 等。

SKU-70316

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 BRAND REVENUE ANALYSIS FOR VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET

TABLE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DTUGS (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DRUGS(NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL MONOCLONAL ANTIIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL PRESCRIPTION BASED IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL OTC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL NASAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL RHINOVIRUS (COMMON COLD) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL INFLUENZA (FLU) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL ADENOVIRUSES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL LOWER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL UPPER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL GERIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL PEDIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL ADULTS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL MALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 GLOBAL FEMALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 50 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 51 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 52 GLOBAL AMBULATORY SURGICAL CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 53 GLOBAL CLINICS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 54 GLOBAL HOME CARE SETTINGS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 55 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 56 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 57 GLOBAL DIRECT TENDER IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 58 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 59 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 60 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 61 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 75 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 76 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 77 NORTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 78 NORTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 79 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 80 NORTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 81 NORTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 82 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 83 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 84 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 85 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 86 NORTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 87 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 88 NORTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 89 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 90 U.S. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 93 U.S. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 94 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 95 U.S. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 96 U.S. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 97 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 98 U.S. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 99 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 101 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 103 U.S. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 104 U.S. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 105 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 106 U.S. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 107 U.S. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 108 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 109 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 110 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 111 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 112 U.S. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 113 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 114 U.S. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 116 CANADA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 119 CANADA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 120 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 121 CANADA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 122 CANADA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 123 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 124 CANADA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 125 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 127 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 129 CANADA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 130 CANADA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 131 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 132 CANADA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 133 CANADA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 134 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 135 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 136 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 137 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 138 CANADA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 139 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 140 CANADA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 141 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 142 MEXICO NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 143 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 145 MEXICO VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 146 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 147 MEXICO WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 148 MEXICO COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 149 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 150 MEXICO INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 151 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 152 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 153 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 154 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 155 MEXICO ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 156 MEXICO INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 157 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 158 MEXICO PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 159 MEXICO ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 160 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 161 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 162 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 163 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 164 MEXICO HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 165 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 166 MEXICO RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 167 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 168 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 169 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 170 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 171 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 172 EUROPE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 173 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 174 EUROPE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 175 EUROPE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 176 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 177 EUROPE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 178 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 179 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 180 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 181 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 182 EUROPE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 183 EUROPE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 184 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 185 EUROPE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 186 EUROPE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 187 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 188 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 189 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 190 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 191 EUROPE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 192 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 193 EUROPE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 194 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 195 GERMANY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 196 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 197 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 198 GERMANY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 199 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 200 GERMANY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 201 GERMANY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 202 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 203 GERMANY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 204 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 205 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 206 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 207 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 208 GERMANY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 209 GERMANY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 210 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 211 GERMANY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 212 GERMANY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 213 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 214 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 215 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 216 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 217 GERMANY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 218 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 219 GERMANY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 220 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 221 FRANCE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 222 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 223 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 224 FRANCE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 225 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 226 FRANCE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 227 FRANCE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 228 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 229 FRANCE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 230 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 231 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 232 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 233 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 234 FRANCE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 235 FRANCE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 236 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 237 FRANCE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 238 FRANCE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 239 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 240 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 241 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 242 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 243 FRANCE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 244 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 245 FRANCE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 246 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 247 U.K. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 249 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 250 U.K. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 251 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 252 U.K. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 253 U.K. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 254 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 255 U.K. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 256 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 257 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 258 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 259 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 260 U.K. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 261 U.K. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 262 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 263 U.K. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 264 U.K. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 265 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 266 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 267 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 268 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 269 U.K. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 270 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 271 U.K. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 272 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 273 ITALY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 274 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 275 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 276 ITALY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 277 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 278 ITALY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 279 ITALY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 280 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 281 ITALY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 282 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 283 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 284 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 285 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 286 ITALY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 287 ITALY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 288 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 289 ITALY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 290 ITALY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 291 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 292 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 293 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 294 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 295 ITALY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 296 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 297 ITALY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 298 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 299 RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 300 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 301 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 302 RUSSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 303 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 304 RUSSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 305 RUSSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 306 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 307 RUSSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 308 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 309 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 310 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 311 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 312 RUSSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 313 RUSSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 314 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 315 RUSSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 316 RUSSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 317 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 318 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 319 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 320 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 321 RUSSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 322 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 323 RUSSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 324 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 325 SPAIN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 327 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 328 SPAIN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 329 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 330 SPAIN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 331 SPAIN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 332 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 333 SPAIN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 334 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 335 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 336 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 337 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 338 SPAIN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 339 SPAIN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 340 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 341 SPAIN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 342 SPAIN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 343 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 344 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 345 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 346 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 347 SPAIN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 348 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 349 SPAIN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 350 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 351 TURKEY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 352 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 353 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 354 TURKEY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 355 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 356 TURKEY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 357 TURKEY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 358 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 359 TURKEY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 360 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 361 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 362 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 363 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 364 TURKEY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 365 TURKEY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 366 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 367 TURKEY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 368 TURKEY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 369 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 370 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 371 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 372 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 373 TURKEY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 374 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 375 TURKEY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 376 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 377 NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 378 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 379 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 380 NETHERLANDS VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 381 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 382 NETHERLANDS WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 383 NETHERLANDS COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 384 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 385 NETHERLANDS INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 386 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 387 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 388 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 389 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 390 NETHERLANDS ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 391 NETHERLANDS INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 392 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 393 NETHERLANDS PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 394 NETHERLANDS ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 395 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 396 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 397 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 398 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 399 NETHERLANDS HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 400 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 401 NETHERLANDS RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 402 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 403 SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 404 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 405 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 406 SWITZERLAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 407 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 408 SWITZERLAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 409 SWITZERLAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 410 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 411 SWITZERLAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 412 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 413 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 414 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 415 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 416 SWITZERLAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 417 SWITZERLAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 418 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 419 SWITZERLAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 420 SWITZERLAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 421 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 422 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 423 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 424 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 425 SWITZERLAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 426 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 427 SWITZERLAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 428 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 429 BELGIUM NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 430 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 431 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 432 BELGIUM VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 433 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 434 BELGIUM WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 435 BELGIUM COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 436 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 437 BELGIUM INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 438 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 439 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 440 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 441 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 442 BELGIUM ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 443 BELGIUM INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 444 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 445 BELGIUM PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 446 BELGIUM ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 447 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 448 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 449 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 450 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 451 BELGIUM HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 452 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 453 BELGIUM RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 454 REST OF EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 455 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 456 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 457 ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 458 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 459 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 460 ASIA-PACIFIC VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 461 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 462 ASIA-PACIFIC WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 463 ASIA-PACIFIC COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 464 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 465 ASIA-PACIFIC INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 466 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 467 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 468 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 469 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 470 ASIA-PACIFIC ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 471 ASIA-PACIFIC INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 472 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 473 ASIA-PACIFIC PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 474 ASIA-PACIFIC ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 475 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 476 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 477 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 478 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 479 ASIA-PACIFIC HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 480 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 481 ASIA-PACIFIC RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 482 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 483 CHINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 484 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 485 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 486 CHINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 487 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 488 CHINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 489 CHINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 490 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 491 CHINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 492 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 493 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 494 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 495 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 496 CHINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 497 CHINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 498 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 499 CHINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 500 CHINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 501 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 502 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 503 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 504 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 505 CHINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 506 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 507 CHINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 508 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 509 JAPAN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 510 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 511 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 512 JAPAN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 513 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 514 JAPAN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 515 JAPAN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 516 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 517 JAPAN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 518 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 519 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 520 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 521 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 522 JAPAN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 523 JAPAN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 524 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 525 JAPAN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 526 JAPAN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 527 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 528 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 529 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 530 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 531 JAPAN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 532 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 533 JAPAN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 534 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 535 INDIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 536 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 537 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 538 INDIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 539 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 540 INDIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 541 INDIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 542 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 543 INDIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 544 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 545 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 546 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 547 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 548 INDIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 549 INDIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 550 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 551 INDIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 552 INDIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 553 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 554 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 555 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 556 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 557 INDIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 558 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 559 INDIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 560 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 561 SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 562 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 563 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 564 SOUTH KOREA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 565 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 566 SOUTH KOREA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 567 SOUTH KOREA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 568 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 569 SOUTH KOREA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 570 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 571 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 572 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 573 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 574 SOUTH KOREA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 575 SOUTH KOREA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 576 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 577 SOUTH KOREA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 578 SOUTH KOREA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 579 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 580 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 581 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 582 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 583 SOUTH KOREA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 584 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 585 SOUTH KOREA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 586 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 587 AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 588 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 589 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 590 AUSTRALIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 591 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 592 AUSTRALIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 593 AUSTRALIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 594 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 595 AUSTRALIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 596 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 597 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 598 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 599 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 600 AUSTRALIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 601 AUSTRALIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 602 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 603 AUSTRALIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 604 AUSTRALIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 605 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 606 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 607 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 608 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 609 AUSTRALIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 610 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 611 AUSTRALIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 612 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 613 SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 614 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 615 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 616 SINGAPORE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 617 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 618 SINGAPORE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 619 SINGAPORE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 620 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 621 SINGAPORE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 622 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 623 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 624 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 625 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 626 SINGAPORE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 627 SINGAPORE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 628 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 629 SINGAPORE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 630 SINGAPORE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 631 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 632 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 633 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 634 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 635 SINGAPORE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 636 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 637 SINGAPORE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 638 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 639 THAILAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 640 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 641 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 642 THAILAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 643 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 644 THAILAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 645 THAILAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 646 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 647 THAILAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 648 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 649 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 650 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 651 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 652 THAILAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 653 THAILAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 654 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 655 THAILAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 656 THAILAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 657 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 658 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 659 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 660 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 661 THAILAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 662 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 663 THAILAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 664 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 665 MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 666 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 667 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 668 MALAYSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 669 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 670 MALAYSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 671 MALAYSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 672 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 673 MALAYSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 674 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 675 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 676 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 677 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 678 MALAYSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 679 MALAYSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 680 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 681 MALAYSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 682 MALAYSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 683 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 684 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 685 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 686 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 687 MALAYSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 688 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 689 MALAYSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 690 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 691 INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 692 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 693 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 694 INDONESIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 695 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 696 INDONESIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 697 INDONESIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 698 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 699 INDONESIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 700 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 701 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 702 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 703 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 704 INDONESIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 705 INDONESIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 706 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 707 INDONESIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 708 INDONESIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 709 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 710 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 711 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 712 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 713 INDONESIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 714 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 715 INDONESIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 716 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 717 PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 718 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 719 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 720 PHILIPPINES VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 721 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 722 PHILIPPINES WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 723 PHILIPPINES COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 724 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 725 PHILIPPINES INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 726 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 727 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 728 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 729 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 730 PHILIPPINES ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 731 PHILIPPINES INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 732 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 733 PHILIPPINES PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 734 PHILIPPINES ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 735 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 736 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 737 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 738 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 739 PHILIPPINES HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 740 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 741 PHILIPPINES RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 742 REST OF ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 743 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 744 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 745 SOUTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 746 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 747 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 748 SOUTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 749 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 750 SOUTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 751 SOUTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 752 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 753 SOUTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 754 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 755 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 756 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 757 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 758 SOUTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 759 SOUTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 760 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 761 SOUTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 762 SOUTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 763 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 764 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 765 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 766 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 767 SOUTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 768 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 769 SOUTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 770 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 771 BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 772 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 773 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 774 BRAZIL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 775 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 776 BRAZIL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 777 BRAZIL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 778 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 779 BRAZIL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 780 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 781 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 782 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 783 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 784 BRAZIL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 785 BRAZIL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 786 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 787 BRAZIL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 788 BRAZIL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 789 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 790 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 791 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 792 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 793 BRAZIL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 794 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 795 BRAZIL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 796 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 797 ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 798 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 799 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 800 ARGENTINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 801 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 802 ARGENTINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 803 ARGENTINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 804 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 805 ARGENTINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 806 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 807 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 808 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 809 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 810 ARGENTINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 811 ARGENTINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 812 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 813 ARGENTINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 814 ARGENTINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 815 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 816 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 817 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 818 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 819 ARGENTINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 820 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 821 ARGENTINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 822 REST OF SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 823 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 824 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 825 MIDDLE EAST AND AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 826 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 827 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 828 MIDDLE EAST AND AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 829 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 830 MIDDLE EAST AND AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 831 MIDDLE EAST AND AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 832 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 833 MIDDLE EAST AND AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 834 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 835 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 836 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 837 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 838 MIDDLE EAST AND AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 839 MIDDLE EAST AND AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 840 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 841 MIDDLE EAST AND AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 842 MIDDLE EAST AND AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 843 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 844 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 845 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 846 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 847 MIDDLE EAST AND AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 848 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 849 MIDDLE EAST AND AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 850 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 851 SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 852 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 853 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 854 SOUTH AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 855 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 856 SOUTH AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 857 SOUTH AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 858 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 859 SOUTH AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 860 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 861 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 862 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 863 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 864 SOUTH AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 865 SOUTH AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 866 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 867 SOUTH AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 868 SOUTH AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 869 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 870 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 871 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 872 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 873 SOUTH AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 874 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 875 SOUTH AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 876 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 877 SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 878 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 879 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 880 SAUDI ARABIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 881 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 882 SAUDI ARABIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 883 SAUDI ARABIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 884 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 885 SAUDI ARABIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 886 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 887 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 888 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 889 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 890 SAUDI ARABIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 891 SAUDI ARABIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 892 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 893 SAUDI ARABIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 894 SAUDI ARABIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 895 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 896 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 897 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 898 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 899 SAUDI ARABIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 900 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 901 SAUDI ARABIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 902 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 903 U.A.E. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 904 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 905 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 906 U.A.E. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 907 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 908 U.A.E. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 909 U.A.E. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 910 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 911 U.A.E. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 912 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 913 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 914 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 915 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 916 U.A.E. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 917 U.A.E. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 918 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 919 U.A.E. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 920 U.A.E. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 921 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 922 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 923 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 924 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 925 U.A.E. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 926 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 927 U.A.E. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 928 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 929 EGYPT NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 930 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 931 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 932 EGYPT VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 933 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 934 EGYPT WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 935 EGYPT COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 936 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 937 EGYPT INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 938 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 939 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 940 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 941 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 942 EGYPT ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 943 EGYPT INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 944 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 945 EGYPT PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 946 EGYPT ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 947 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 948 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 949 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 950 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 951 EGYPT HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 952 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 953 EGYPT RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 954 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

TABLE 955 ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 956 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 957 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 958 ISRAEL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)

TABLE 959 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 960 ISRAEL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 961 ISRAEL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 962 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)

TABLE 963 ISRAEL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)

TABLE 964 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 965 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)

TABLE 966 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 967 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 968 ISRAEL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 969 ISRAEL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 970 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 971 ISRAEL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 972 ISRAEL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)

TABLE 973 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)

TABLE 974 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)

TABLE 975 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 976 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 977 ISRAEL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 978 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 979 ISRAEL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 980 REST OF MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)

图片列表

FIGURE 1 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET AND GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 11 THE INCREASING PREVALENCE OF VIRAL RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 12 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN 2024 AND 2031

FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET

FIGURE 15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2023

FIGURE 16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2024-2031 (USD MILLION)

FIGURE 17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 18 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2023

FIGURE 20 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 21 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 24 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)

FIGURE 25 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 26 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 27 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2023

FIGURE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2024-2031 (USD MILLION)

FIGURE 29 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 30 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2023

FIGURE 32 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2024-2031 (USD MILLION)

FIGURE 33 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, CAGR (2024-2031)

FIGURE 34 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 35 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2023

FIGURE 36 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2024-2031 (USD MILLION)

FIGURE 37 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, CAGR (2024-2031)

FIGURE 38 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, LIFELINE CURVE

FIGURE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2023

FIGURE 40 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 41 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 43 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2023

FIGURE 44 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 45 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, CAGR (2024-2031)

FIGURE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 48 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 50 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SNAPSHOT (2023)

FIGURE 52 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 53 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 AISA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What are the primary segments covered in the Global Viral Respiratory Infections Treatment Market report?

The market is segmented based on , By Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031. .

What is the current market size of the Global Viral Respiratory Infections Treatment Market?

The Global Viral Respiratory Infections Treatment Market size was valued at USD 57365.34 USD Million in 2023.

What is the expected growth rate of the Global Viral Respiratory Infections Treatment Market?

The Global Viral Respiratory Infections Treatment Market is projected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2031.

Who are the key players in the Global Viral Respiratory Infections Treatment Market?

The major players operating in the market include Pfizer, GSK, Gilead Sciences, F. Hoffmann La Roche, Johnson & Johnson, SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals, Bharat Biotech, Swedish Orphan Biovitrum AB, Serum Institute of India Pvt. , Biological E Limited, Celltrion Healthcare Co., InflaRx N.V..

Which countries are analyzed in the Global Viral Respiratory Infections Treatment Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa.

全球病毒性呼吸道感染治疗市场 – 行业趋势和 2031 年预测

全球病毒性呼吸道感染治疗市场 – 行业趋势和 2031 年预测

Global Viral Respiratory Infections Treatment Market

CAGR : 8.50 %

病毒性呼吸道感染治疗市场分析及规模

全球病毒性呼吸道感染治疗市场动态

全球病毒性呼吸道感染治疗市场范围

全球病毒性呼吸道感染治疗市场区域分析/见解

竞争格局和全球病毒性呼吸道感染治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

全球病毒性呼吸道感染治疗市场 – 行业趋势和 2031 年预测

全球病毒性呼吸道感染治疗市场 – 行业趋势和 2031 年预测

Global Viral Respiratory Infections Treatment Market

CAGR : 8.50 %

病毒性呼吸道感染治疗市场分析及规模

全球病毒性呼吸道感染治疗市场动态

全球病毒性呼吸道感染治疗市场范围

全球病毒性呼吸道感染治疗市场区域分析/见解

竞争格局和全球病毒性呼吸道感染治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面